دورة المؤشرنت للتحليل الفني
50 دينار كويتي
أسهم على بابا والاربعين حرامي
- بادئ الموضوع m&m
- تاريخ البدء
عائض بن فيصل ال رشيد
عضو محترف
عائض بن فيصل ال رشيد
عضو محترف
15 ديسمبر
2 من اربعه الاول كاتب فيه تقرير جميل جدا والاهداف عالية من 2.5 الى 6
لكن للاسف غير شرعي استبعدته اذا
STKR - Buy Range - $1.25 to $1.50 (risk to a break below the $1.13 area). Sell Range - $2.25 to $2.50. Previous close - $1.47.
هذا السهم تمت التوصيه عليه 9 نوفمبر
السهم الثاني هو:
STG - Buy Range - $0.75 to $1.00 (risk to a break below the $0.68 area). Sell Range - $1.50 to $2.00. Previous close - $0.75.
شفت بياناتها في الياهو جيده كلها يعني ارتفاع ان شاء الله
http://finance.yahoo.com/q?s=STG
الاسهم للتجربه وماشيه لحد الان درجة جيد جدا
بل ان شاء الله تصيب الاهداف ونقدر نقول عليه ممتاز
اخي قاصد كريم مشكور على الشارتات جزاك الله خير
2 من اربعه الاول كاتب فيه تقرير جميل جدا والاهداف عالية من 2.5 الى 6
لكن للاسف غير شرعي استبعدته اذا
STKR - Buy Range - $1.25 to $1.50 (risk to a break below the $1.13 area). Sell Range - $2.25 to $2.50. Previous close - $1.47.
هذا السهم تمت التوصيه عليه 9 نوفمبر
السهم الثاني هو:
STG - Buy Range - $0.75 to $1.00 (risk to a break below the $0.68 area). Sell Range - $1.50 to $2.00. Previous close - $0.75.
شفت بياناتها في الياهو جيده كلها يعني ارتفاع ان شاء الله
http://finance.yahoo.com/q?s=STG
الاسهم للتجربه وماشيه لحد الان درجة جيد جدا
بل ان شاء الله تصيب الاهداف ونقدر نقول عليه ممتاز
اخي قاصد كريم مشكور على الشارتات جزاك الله خير
16 ديسمبر
2 من اصل 4 أسهم
تقرير عن سهم neng للمره الثالثه (معاد)
Stocks to watch:
NENG - we last highlighted Network Engines (NENG) late last month in our November 29th report after the stock had closed the previous session at $2.49. Since then the stock has bantered around in a narrow range roughly between the $2.20 and $2.60 area. However, in the past few sessions it has popped higher to trade between the $2.60 and $3.00 area and closed yesterday with a gain of nearly 8 1/2% to finish at $2.72 on heavier than normal trading volume. It is now very near the high end of our original listed buy range and the near term technicals suggest it could be ready to break to the upside in the near future so we decided to revisit it again today. The recent pop higher from below the $1.80 area (see a near term price chart for details) has given this stock a green light for moving higher still and little has changed to suggest otherwise, laying the groundwork for a potential move back up to the $3.50 level.
Network Engines, Inc. develops, manufactures and distributes server appliances that enable network equipment providers and independent software vendors (ISVs) to deliver data storage and security networking applications to their customers. The Company is focused on providing its strategic partners with server appliance hardware, integration services and appliance development, manufacturing, fulfillment, distribution and post-sale support to allow these strategic partners to deliver turnkey solutions to their end user customers. The server appliance is sold and supported either by the Company's ISV partners, or, alternatively, by the Company through its distribution operation. Server appliances are pre-configured computer network infrastructure devices designed to deliver specific application functionality.
As previously stated, several key near term technicals got the go ahead for Network Engines following its recent move higher. Money flow into the stock recently shot up to levels not seen since late April of this year when the stock was trading between the $3.50 and $4.00 range and the close yesterday at $2.72 clearly set it above the high end of our set Bollinger Band parameters, suggesting further upside movement is likely over the next several sessions. Couple that with a near term relative strength picture that recently corrected from near overbought conditions and looks poised to resume its move higher and a shorter term stochastic picture that is rising rapidly from mid range after correcting from near overbought levels late last month and you've got a decent picture of a stock on the march higher. We think this one's worth a watch, so we're making it our first spec play of the day (below) as the trading week begins this morning.
Spec Plays:
NENG - Buy Range - $2.25 to $2.75 (risk to a break below the $2.00 area). Sell Range - $3.75 to $4.25. Previous close - $2.72.
VRA - Buy Range - $1.00 to $1.25 (risk to a break below the $0.85 area). Sell Range - $1.75 to $2.00. Previous close - $1.07.
وهذا السهم البيوتكنولوجي ايضا سبق طرحة
2 من اصل 4 أسهم
تقرير عن سهم neng للمره الثالثه (معاد)
Stocks to watch:
NENG - we last highlighted Network Engines (NENG) late last month in our November 29th report after the stock had closed the previous session at $2.49. Since then the stock has bantered around in a narrow range roughly between the $2.20 and $2.60 area. However, in the past few sessions it has popped higher to trade between the $2.60 and $3.00 area and closed yesterday with a gain of nearly 8 1/2% to finish at $2.72 on heavier than normal trading volume. It is now very near the high end of our original listed buy range and the near term technicals suggest it could be ready to break to the upside in the near future so we decided to revisit it again today. The recent pop higher from below the $1.80 area (see a near term price chart for details) has given this stock a green light for moving higher still and little has changed to suggest otherwise, laying the groundwork for a potential move back up to the $3.50 level.
Network Engines, Inc. develops, manufactures and distributes server appliances that enable network equipment providers and independent software vendors (ISVs) to deliver data storage and security networking applications to their customers. The Company is focused on providing its strategic partners with server appliance hardware, integration services and appliance development, manufacturing, fulfillment, distribution and post-sale support to allow these strategic partners to deliver turnkey solutions to their end user customers. The server appliance is sold and supported either by the Company's ISV partners, or, alternatively, by the Company through its distribution operation. Server appliances are pre-configured computer network infrastructure devices designed to deliver specific application functionality.
As previously stated, several key near term technicals got the go ahead for Network Engines following its recent move higher. Money flow into the stock recently shot up to levels not seen since late April of this year when the stock was trading between the $3.50 and $4.00 range and the close yesterday at $2.72 clearly set it above the high end of our set Bollinger Band parameters, suggesting further upside movement is likely over the next several sessions. Couple that with a near term relative strength picture that recently corrected from near overbought conditions and looks poised to resume its move higher and a shorter term stochastic picture that is rising rapidly from mid range after correcting from near overbought levels late last month and you've got a decent picture of a stock on the march higher. We think this one's worth a watch, so we're making it our first spec play of the day (below) as the trading week begins this morning.
Spec Plays:
NENG - Buy Range - $2.25 to $2.75 (risk to a break below the $2.00 area). Sell Range - $3.75 to $4.25. Previous close - $2.72.
VRA - Buy Range - $1.00 to $1.25 (risk to a break below the $0.85 area). Sell Range - $1.75 to $2.00. Previous close - $1.07.
وهذا السهم البيوتكنولوجي ايضا سبق طرحة
$$ الطمـــوح $$
عضو نشط
- التسجيل
- 12 أغسطس 2004
- المشاركات
- 476
الله يعطيك العافيه أخوي M&m
وموفق إنشاء الله
توصيات جميله وأخبار ولا أروع
بس تدري وش اللي عاجبني أكثر
إن أغلب أسهمك إذا مو كلها إن أسعارها حلوه وخصوصا للمبتدئين أمثالي :d
والله يجزاك خير ويجعلها في ميزان أعمالك أنت والأخ قاصد
أخوكم
أبوأحمد
وموفق إنشاء الله
توصيات جميله وأخبار ولا أروع
بس تدري وش اللي عاجبني أكثر
إن أغلب أسهمك إذا مو كلها إن أسعارها حلوه وخصوصا للمبتدئين أمثالي :d
والله يجزاك خير ويجعلها في ميزان أعمالك أنت والأخ قاصد
أخوكم
أبوأحمد
طموح شكرا
هذه توصيات والباقي على الله واشوف ايضا تستاهل المراقبه ودراستها فنيا
اما الاسعار
هي خصيصا الرولينج ستوك اي سهم يمشي بقناة عليا وسفللى لمدة معينه
وايضا للاسهم الاندر فاليو الغير مطابقه لسعرها الحالي اي اقل
وايضا microcap stocks priced under $5. للمكيروكاب اقل من 5 دولار
بالتوفيق
الرولينج كهذا
هذه توصيات والباقي على الله واشوف ايضا تستاهل المراقبه ودراستها فنيا
اما الاسعار
هي خصيصا الرولينج ستوك اي سهم يمشي بقناة عليا وسفللى لمدة معينه
وايضا للاسهم الاندر فاليو الغير مطابقه لسعرها الحالي اي اقل
وايضا microcap stocks priced under $5. للمكيروكاب اقل من 5 دولار
بالتوفيق
الرولينج كهذا
الملفات المرفقه:
$$ الطمـــوح $$
عضو نشط
- التسجيل
- 12 أغسطس 2004
- المشاركات
- 476
مشكور على الشرح
واللي فهمته:
بما أنك تأخذها من القاع وعند رجوعها للأعلى فأتوقع أنها تصلح للإستثمار؟؟
هل هذا صحيح؟؟
وموفق إنشاء الله
واللي فهمته:
بما أنك تأخذها من القاع وعند رجوعها للأعلى فأتوقع أنها تصلح للإستثمار؟؟
هل هذا صحيح؟؟
وموفق إنشاء الله
قصير الاجل
ليست الا سوينج
اكتب كل الاسهم في ورقة خارجية وتابعها وانا ايضا وخاصة اركز على تقريرهم
الموقع مثل الفاند (المحافظ الاستثماريه)بعد الله وتوفيقه ضامناسترجاع المال الذي دفعته ان لم يتوفق الاسهم
ناس محترمين
نشوف اسهمهم ويعدين لنا كلام
لحد الان اعطيه B+ جيد جدا مرتفع
الموقع وصى على AKAM عندما كانت 2 دولار
والان12 ووصل الى مستويات عالية
وايضا وصى على BFUN عندما كانت .97 سنت ووصلت الى 3.5 دولار خلال 15 يوم ولان .15 سنت على ما اعتقد
اذا لابد ددراسة السهم على الاقل بشكل مبسط والاقتناع به
ليست الا سوينج
اكتب كل الاسهم في ورقة خارجية وتابعها وانا ايضا وخاصة اركز على تقريرهم
الموقع مثل الفاند (المحافظ الاستثماريه)بعد الله وتوفيقه ضامناسترجاع المال الذي دفعته ان لم يتوفق الاسهم
ناس محترمين
نشوف اسهمهم ويعدين لنا كلام
لحد الان اعطيه B+ جيد جدا مرتفع
الموقع وصى على AKAM عندما كانت 2 دولار
والان12 ووصل الى مستويات عالية
وايضا وصى على BFUN عندما كانت .97 سنت ووصلت الى 3.5 دولار خلال 15 يوم ولان .15 سنت على ما اعتقد
اذا لابد ددراسة السهم على الاقل بشكل مبسط والاقتناع به
17 ديسمبر كاتب تقرير عن سهم dytk
Stocks to watch:
DYTK - okay, this one's NOT for the faint of heart. We last mentioned Dyntek Inc (DYTK) exactly a month ago in our November 17th report as a spec play after the stock had closed the previous session at $0.74. The stock promptly rose to a near term high of $0.87 before beginning a steady decline that led it back down to near its late October lows near the $0.50 area early last week. Can you say double bottom formation? We thought you could. Anyway, since then the stock has been stair stepping higher and the near term technicals have now lined up for an even more positive picture than before. While the stock closed a penny lower yesterday at $0.61 per share, good news out before the bell this morning is helping to push it noticeably higher in early trading on heavier than normal volume. If this stock gets some upside legs, we think given the positive tone of the near term technicals, a return to its mid April highs in the $1.50 to $2.00 area is quite possible over the next few weeks.
DynTek, Inc. is a professional services firm that specializes in information technology (IT) solutions and business process outsource services for state and local government agencies through its sole active subsidiary, DynTek Services, Inc. The Company provides IT support services and enabling technologies, as well as related products, to state and local government customers. The Company's comprehensive IT services includes security consulting, infrastructure planning and deployment, information technology application development, legacy systems integration, information technology system support and business process outsourcing services for state and local government agencies. The Company conducts its operations in two segments, Information Technology Services and Business Process Outsourcing Services.
As stated earlier, the near term technicals for Dyntek look very positive. Money flow into this stock is nearing an all time high and if these indicators bust through the mid April highs, it could be the confirmation needed that the stock is headed much, much higher. The near term relative strength indicators, which have been flatlining around mid range since late last month, appear to be turning higher once again, with plenty of upside left in them before threatening an overbought condition. The MACD line has crossed over to a positive trend and the shorter term stochastics are just starting to rise noticeably from the oversold line, also with lots of upside left in them before reaching overbought status. One final note, the stock has already traded over 4 times its average daily volume in the first few minutes of trading this morning and is up a few cents from yesterday's close, indicating possible continued transfer of the stock from weak hands into strong hands. We think this one's definitely worth a gander if you get the chance. Just remember, it's volatile and not for the weak of heart.
Spec Plays:
DYTK - Buy Range - $0.63 to $0.75 (risk to a break below the $0.48 area). Sell Range - $1.25 to $1.50. Previous close - $0.61.
-وكاتب تقرير عنه ايضا 17 نوفمبر ولكن بعد الازمة التي حصلت رشح السهم مره اخرى
--------------------------------------------------------------------------------
Stocks to watch:
DYTK - okay, this one's NOT for the faint of heart. We last mentioned Dyntek Inc (DYTK) exactly a month ago in our November 17th report as a spec play after the stock had closed the previous session at $0.74. The stock promptly rose to a near term high of $0.87 before beginning a steady decline that led it back down to near its late October lows near the $0.50 area early last week. Can you say double bottom formation? We thought you could. Anyway, since then the stock has been stair stepping higher and the near term technicals have now lined up for an even more positive picture than before. While the stock closed a penny lower yesterday at $0.61 per share, good news out before the bell this morning is helping to push it noticeably higher in early trading on heavier than normal volume. If this stock gets some upside legs, we think given the positive tone of the near term technicals, a return to its mid April highs in the $1.50 to $2.00 area is quite possible over the next few weeks.
DynTek, Inc. is a professional services firm that specializes in information technology (IT) solutions and business process outsource services for state and local government agencies through its sole active subsidiary, DynTek Services, Inc. The Company provides IT support services and enabling technologies, as well as related products, to state and local government customers. The Company's comprehensive IT services includes security consulting, infrastructure planning and deployment, information technology application development, legacy systems integration, information technology system support and business process outsourcing services for state and local government agencies. The Company conducts its operations in two segments, Information Technology Services and Business Process Outsourcing Services.
As stated earlier, the near term technicals for Dyntek look very positive. Money flow into this stock is nearing an all time high and if these indicators bust through the mid April highs, it could be the confirmation needed that the stock is headed much, much higher. The near term relative strength indicators, which have been flatlining around mid range since late last month, appear to be turning higher once again, with plenty of upside left in them before threatening an overbought condition. The MACD line has crossed over to a positive trend and the shorter term stochastics are just starting to rise noticeably from the oversold line, also with lots of upside left in them before reaching overbought status. One final note, the stock has already traded over 4 times its average daily volume in the first few minutes of trading this morning and is up a few cents from yesterday's close, indicating possible continued transfer of the stock from weak hands into strong hands. We think this one's definitely worth a gander if you get the chance. Just remember, it's volatile and not for the weak of heart.
Spec Plays:
DYTK - Buy Range - $0.63 to $0.75 (risk to a break below the $0.48 area). Sell Range - $1.25 to $1.50. Previous close - $0.61.
-وكاتب تقرير عنه ايضا 17 نوفمبر ولكن بعد الازمة التي حصلت رشح السهم مره اخرى
--------------------------------------------------------------------------------
20 سبتمر
لا العلم شرعيتها او قراءت عنها
Stocks to watch:
AVII - given the recent bad news out on some heavyweight pharmaceutical companies' products (i.e., the cox II inhibitor class that includes VIOXX and most recently Celebrex), one may think it a bad time to look toward the biotech secor. That said, all's not lost in biotech land. In fact, the contrarian in us is looking, as always, at opportunity. We've mentioned Avi Biopharma (AVII) on more than one occasion in the past several weeks. However, the stock has remained in a rather narrow trading range roughly between the $2.00 and $2.50 area since mid September of this year. During that same time frame though, key divergences between the stock's price performance and some of its other technical indicators have been developing to a point to where they're just to glaring to ignore. Shares of AVII rose over 10% in Friday's otherwise lackluster market to close near their high of the day at $2.30 on very heavy trading volume. This type of accumulation has been going on for some time and we think that this stock could be getting ready to break out of its three month trading channel to the upside. If it does, shares of AVII could be headed back to the $3.50 to $4.00 area in relatively short order with only limited upside chart resistance coming in around the $2.75 area.
AVI Biopharma, Inc. (AVI) is a biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Its principal products in development target life threatening diseases, including cardiovascular disease, infectious disease and cancer. The Company has completed preclinical and some clinical studies, using its NEUGENE drugs in the treatment of cardiovascular disease, infectious disease, cancer and polycystic kidney disease (PKD), and in regulating drug metabolism. It has completed four Phase I trials in drug metabolism program, and two Phase Ib trials in cancer and polycystic kidney disease programs.
Money flow into Avi Biopharma has been on a fairly pronounced uptrend since late May of this year. While the stock's price continued to decline from late May (when it was trading roughly in the $2.25 area to early August of this year (when it hit it's 52 week low of $1.55), institutional and astute investors (the so called 'smart money') continued snatching up shares of the company and at this point money flow is at its highest level in over a year. The stock's close at $2.30 on Friday also put it above the high end of our set Bollinger Band parameters, suggesting continued upside movement is probable over the next few sessions. That indicator however could be skewed by what will obviously be some thin trading this week for the entire market. The stock's near term relative strength indicators are rising, but have just hit mid range, so there's plenty of upside left in them before threatening an overbought condition. Finally, the shorter term stochastics are also rising sharply, but are doing so from oversold territory with lots of upside left in them. We think this one's worth a watch folks, so we're making it our first spec play of the day (below) this morning.
Spec plays:
AVII - Buy Range - $2.25 to $2.50 (risk to a break below the $1.88 area). Sell Range - $3.50 to $4.00. Previous close - $2.30.
SYBR - Buy Range - $3.25 to $3.75 (risk to a break below the $2.88 area). Sell Range - $5.50 to $6.00. Previous close - $3.69.
SQNM - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.75. Previous close - $1.47.
BIOM - Buy Range - $2.50 to $2.75 (risk to a break below the $2.22 area). Sell Range - $4.00 to $5.00. Previous close - $2.64.
21 لم ياتي
لا العلم شرعيتها او قراءت عنها
Stocks to watch:
AVII - given the recent bad news out on some heavyweight pharmaceutical companies' products (i.e., the cox II inhibitor class that includes VIOXX and most recently Celebrex), one may think it a bad time to look toward the biotech secor. That said, all's not lost in biotech land. In fact, the contrarian in us is looking, as always, at opportunity. We've mentioned Avi Biopharma (AVII) on more than one occasion in the past several weeks. However, the stock has remained in a rather narrow trading range roughly between the $2.00 and $2.50 area since mid September of this year. During that same time frame though, key divergences between the stock's price performance and some of its other technical indicators have been developing to a point to where they're just to glaring to ignore. Shares of AVII rose over 10% in Friday's otherwise lackluster market to close near their high of the day at $2.30 on very heavy trading volume. This type of accumulation has been going on for some time and we think that this stock could be getting ready to break out of its three month trading channel to the upside. If it does, shares of AVII could be headed back to the $3.50 to $4.00 area in relatively short order with only limited upside chart resistance coming in around the $2.75 area.
AVI Biopharma, Inc. (AVI) is a biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Its principal products in development target life threatening diseases, including cardiovascular disease, infectious disease and cancer. The Company has completed preclinical and some clinical studies, using its NEUGENE drugs in the treatment of cardiovascular disease, infectious disease, cancer and polycystic kidney disease (PKD), and in regulating drug metabolism. It has completed four Phase I trials in drug metabolism program, and two Phase Ib trials in cancer and polycystic kidney disease programs.
Money flow into Avi Biopharma has been on a fairly pronounced uptrend since late May of this year. While the stock's price continued to decline from late May (when it was trading roughly in the $2.25 area to early August of this year (when it hit it's 52 week low of $1.55), institutional and astute investors (the so called 'smart money') continued snatching up shares of the company and at this point money flow is at its highest level in over a year. The stock's close at $2.30 on Friday also put it above the high end of our set Bollinger Band parameters, suggesting continued upside movement is probable over the next few sessions. That indicator however could be skewed by what will obviously be some thin trading this week for the entire market. The stock's near term relative strength indicators are rising, but have just hit mid range, so there's plenty of upside left in them before threatening an overbought condition. Finally, the shorter term stochastics are also rising sharply, but are doing so from oversold territory with lots of upside left in them. We think this one's worth a watch folks, so we're making it our first spec play of the day (below) this morning.
Spec plays:
AVII - Buy Range - $2.25 to $2.50 (risk to a break below the $1.88 area). Sell Range - $3.50 to $4.00. Previous close - $2.30.
SYBR - Buy Range - $3.25 to $3.75 (risk to a break below the $2.88 area). Sell Range - $5.50 to $6.00. Previous close - $3.69.
SQNM - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.75. Previous close - $1.47.
BIOM - Buy Range - $2.50 to $2.75 (risk to a break below the $2.22 area). Sell Range - $4.00 to $5.00. Previous close - $2.64.
21 لم ياتي
بعض الاسهم لم اذكرها وارتفعت بشكل حلو...
وهو سهم vcmp ... التوصية بتاريخ 8 ديسمبر 1.69 وصل بتاريخ اليوم 2.95 دولار
بسبب عقد او كونتراكت مع شركة اخرى وهو مجالها التعليم عن طريق اونلاين بنظام e-learining system
على العموم التوصيات للمتابعه والهدف يب له صبر
الاخوان اللي شروا dytk و vsnt اتمنى احد غيري يفيد كم
والصبر زين
الموقع سوف اذكره وهو باشتراك بسيط جدا يغني عن اكثر المواقع وبسيط
واشتراكي يستمر لحد 10 ايام وسوف اذكر ما فيه وللي يبي يشترك افضل له خاصة انه مو غالي وسامحونا لو جا قصور
اتمنى ان هذا الموقع يفيد ويكون سبب في دعائكم لي وليس علي
الموقع ممتاز
هو
http://www.azforum.net/index.htm
وهو سهم vcmp ... التوصية بتاريخ 8 ديسمبر 1.69 وصل بتاريخ اليوم 2.95 دولار
بسبب عقد او كونتراكت مع شركة اخرى وهو مجالها التعليم عن طريق اونلاين بنظام e-learining system
على العموم التوصيات للمتابعه والهدف يب له صبر
الاخوان اللي شروا dytk و vsnt اتمنى احد غيري يفيد كم
والصبر زين
الموقع سوف اذكره وهو باشتراك بسيط جدا يغني عن اكثر المواقع وبسيط
واشتراكي يستمر لحد 10 ايام وسوف اذكر ما فيه وللي يبي يشترك افضل له خاصة انه مو غالي وسامحونا لو جا قصور
اتمنى ان هذا الموقع يفيد ويكون سبب في دعائكم لي وليس علي
الموقع ممتاز
هو
http://www.azforum.net/index.htm
عائض بن فيصل ال رشيد
عضو محترف
الله يجزاك خير
تقرير 22/ديسمبر
تاكدو من اجتيازها للفتر
December 22, 2004 8:43 am(CST)
A-Z Morning Report
The Dow Jones Industrials closed at a three and a half year high yesterday as stocks roared ahead powered by an upgrade on chip giant Intel that sent investors scrambling to buy tech stocks. In what turned out to be a broad based rally, the blue chip index gained nearly 98 points to finish the day at 10,759.43, a closing level it had not acheived since June 2001. The tech driven Nasdaq Composite roared ahead by more than 23 points to close out the session at 2,150.91, while the small cap Russell 2000 gained over 8 points to end a couple of points from its all time high at 646.20. The trick will be to see if there is any follow through of buying in today's session, but there's little doubt Santa has made his presence known on Wall Street this Christmas.
Months ago we predicted the bulls would run rampant on Wall and Broad if G.W. was re-elected to a second term and here we are folks. We didn't plug a particular candidate or party mind you, we just wanted those of you new to stock trading to understand there's times where events outside the corporate world can affect the mindset of equity investors and traders enmasse. This is one of those times when business and politics have met at a crossroads and so far, they've meshed well together. If you go back and study the re-elections of Ronald Reagan and William Jefferson Clinton, you'll see a similar reaction by the U.S. equity markets in the time betweeen their re-election and the inauguration to their second term...
Stocks to watch:
EPMN - we know, we know - the drug manufacturers (really the pharmaceutical companies) have taken it on the chin lately, but here's a little company whose near term technicals look too powerful to ignore. Shares of Epimmune Inc (EPMN) rose nearly 6% in yesterday's session to close at $1.67 after hitting an intraday high of $1.94 on very heavy trading volume. The move came after the company provided the markets with an update on its ongoing clinical development programs with its EP -2101 therapeutic cancer vaccine and its EP - 1090 therapeutic HIV vaccine. The move helped improve the stock's near term technical outlook which had been slowly painting a bullish picture since early last month. Although Epimmune ended well off of its high of the day, the buying interest in the stock has been improving dramatically over the past couple of months and if it continues to build, we may see this one head back to the $2.50 to $3.00 area in the not too distant future.
Epimmune Inc. is focused on the development of therapeutic vaccines that use multiple epitopes, or protein fragments to specifically activate the body's immune system for the more effective management of infectious diseases and cancer. In September 2002, the Company commenced a Phase I/II clinical trial of its therapeutic, multi-epitope vaccine candidate, EP HIV-1090, in patients infected with human immunodeficiency virus (HIV) 1, which is the predominant strain of HIV in North America and Western Europe. Patients enrolled in the trial are immunized while receiving multiple antiretroviral drugs. In February 2003, it also commenced two Phase I/II clinical trials of its therapeutic, multi-epitope vaccine candidate EP-2101, one in patients with lung cancer and one in patients with colorectal cancer. In addition, it conducts research and preclinical development of vaccines to treat breast, prostate and other cancers under contracts from the National Institutes of Health (NIH).
Although this stock has somewhat of a history of volatility and wild swings, there's little doubt that money flow into Epimmune has been rising dramatically since early last month and is now very near at least a five year high, even higher than it was back in early 2001 when the stock spiked to the $7.00 area. The near term relative strength indicators have been basically range bound at mid level for the past couple of months with minor bumps higher to near the overbought line before returning back to mid range, where they are now. There does appear to be a slight upward bias to them at this stage though. After rising dramatically early this month from extremely oversold levels, the shorter term stochastics have corrected a bit from near overbought levels, a healthy sign in our book. We think this stock could just be on the verge of a handsome move higher, so we're making it our first selection below this morning as a spec play.
Spec Plays:
سهم بيوتكنولوجي
EPMN - Buy Range - $1.50 to $1.75 (risk to a break below the $1.30 area). Sell Range - $2.50 to $3.00. Previous close - $1.67.
MBAY - Buy Range - $1.50 to $1.75 (risk to a break below the $1.20 area). Sell Range - $2.50 to $3.00. Previous close - $1.59.
VIGN - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.50. Previous close - $1.45.
MANU - Buy Range - $2.50 to $3.00 (risk to a break below the $2.25 area). Sell Range - $4.50 to $5.00. Previous close - $2.85.
تاكدو من اجتيازها للفتر
December 22, 2004 8:43 am(CST)
A-Z Morning Report
The Dow Jones Industrials closed at a three and a half year high yesterday as stocks roared ahead powered by an upgrade on chip giant Intel that sent investors scrambling to buy tech stocks. In what turned out to be a broad based rally, the blue chip index gained nearly 98 points to finish the day at 10,759.43, a closing level it had not acheived since June 2001. The tech driven Nasdaq Composite roared ahead by more than 23 points to close out the session at 2,150.91, while the small cap Russell 2000 gained over 8 points to end a couple of points from its all time high at 646.20. The trick will be to see if there is any follow through of buying in today's session, but there's little doubt Santa has made his presence known on Wall Street this Christmas.
Months ago we predicted the bulls would run rampant on Wall and Broad if G.W. was re-elected to a second term and here we are folks. We didn't plug a particular candidate or party mind you, we just wanted those of you new to stock trading to understand there's times where events outside the corporate world can affect the mindset of equity investors and traders enmasse. This is one of those times when business and politics have met at a crossroads and so far, they've meshed well together. If you go back and study the re-elections of Ronald Reagan and William Jefferson Clinton, you'll see a similar reaction by the U.S. equity markets in the time betweeen their re-election and the inauguration to their second term...
Stocks to watch:
EPMN - we know, we know - the drug manufacturers (really the pharmaceutical companies) have taken it on the chin lately, but here's a little company whose near term technicals look too powerful to ignore. Shares of Epimmune Inc (EPMN) rose nearly 6% in yesterday's session to close at $1.67 after hitting an intraday high of $1.94 on very heavy trading volume. The move came after the company provided the markets with an update on its ongoing clinical development programs with its EP -2101 therapeutic cancer vaccine and its EP - 1090 therapeutic HIV vaccine. The move helped improve the stock's near term technical outlook which had been slowly painting a bullish picture since early last month. Although Epimmune ended well off of its high of the day, the buying interest in the stock has been improving dramatically over the past couple of months and if it continues to build, we may see this one head back to the $2.50 to $3.00 area in the not too distant future.
Epimmune Inc. is focused on the development of therapeutic vaccines that use multiple epitopes, or protein fragments to specifically activate the body's immune system for the more effective management of infectious diseases and cancer. In September 2002, the Company commenced a Phase I/II clinical trial of its therapeutic, multi-epitope vaccine candidate, EP HIV-1090, in patients infected with human immunodeficiency virus (HIV) 1, which is the predominant strain of HIV in North America and Western Europe. Patients enrolled in the trial are immunized while receiving multiple antiretroviral drugs. In February 2003, it also commenced two Phase I/II clinical trials of its therapeutic, multi-epitope vaccine candidate EP-2101, one in patients with lung cancer and one in patients with colorectal cancer. In addition, it conducts research and preclinical development of vaccines to treat breast, prostate and other cancers under contracts from the National Institutes of Health (NIH).
Although this stock has somewhat of a history of volatility and wild swings, there's little doubt that money flow into Epimmune has been rising dramatically since early last month and is now very near at least a five year high, even higher than it was back in early 2001 when the stock spiked to the $7.00 area. The near term relative strength indicators have been basically range bound at mid level for the past couple of months with minor bumps higher to near the overbought line before returning back to mid range, where they are now. There does appear to be a slight upward bias to them at this stage though. After rising dramatically early this month from extremely oversold levels, the shorter term stochastics have corrected a bit from near overbought levels, a healthy sign in our book. We think this stock could just be on the verge of a handsome move higher, so we're making it our first selection below this morning as a spec play.
Spec Plays:
سهم بيوتكنولوجي
EPMN - Buy Range - $1.50 to $1.75 (risk to a break below the $1.30 area). Sell Range - $2.50 to $3.00. Previous close - $1.67.
MBAY - Buy Range - $1.50 to $1.75 (risk to a break below the $1.20 area). Sell Range - $2.50 to $3.00. Previous close - $1.59.
VIGN - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.50. Previous close - $1.45.
MANU - Buy Range - $2.50 to $3.00 (risk to a break below the $2.25 area). Sell Range - $4.50 to $5.00. Previous close - $2.85.
قاصد كريم شكرا والله يوفق الجميع
خنجر نعم انها كذلك مغارة علي بابا
ولكن الحظ يلعب دور
والدليل على ذلك vcmp
وامامي ورق بخط يدي صفحة ونصف والاخير قلت هذا اقل سهم ولم يعجبني وطلع امس فقط 60%
المغارة للدراسة والدخول للشجعان والاسهم ان شاء الله تكون ذهب ولماس
على العموم انا ابستمر في تقريرهم ولكم الحكم بعد ذلك
اما انا فاشوف الموقع ممتاز لحد الان والصبر مفتاح الفرج
ملاحظة هامة: اثناء التسجيل يرجى الضغط مره واحده فقط حتى لو طلعت الصفحة التالية توحي بان هناك غلط
البريد سوف يرسل لك كلمة المرور واليوزر نيم
خنجر نعم انها كذلك مغارة علي بابا
ولكن الحظ يلعب دور
والدليل على ذلك vcmp
وامامي ورق بخط يدي صفحة ونصف والاخير قلت هذا اقل سهم ولم يعجبني وطلع امس فقط 60%
المغارة للدراسة والدخول للشجعان والاسهم ان شاء الله تكون ذهب ولماس
على العموم انا ابستمر في تقريرهم ولكم الحكم بعد ذلك
اما انا فاشوف الموقع ممتاز لحد الان والصبر مفتاح الفرج
ملاحظة هامة: اثناء التسجيل يرجى الضغط مره واحده فقط حتى لو طلعت الصفحة التالية توحي بان هناك غلط
البريد سوف يرسل لك كلمة المرور واليوزر نيم
تقرير 23 ديسمبر لسهم غير شرعي
2 من اصل اربعه
IIP - Buy Range - $0.75 to $1.00 (risk to a break below the $0.60 area). Sell Range - $1.50 to $1.75. Previous close - $0.81.
IMNR - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.50. Previous close - $1.40.
والاخير بيوتكنولوجي
2 من اصل اربعه
IIP - Buy Range - $0.75 to $1.00 (risk to a break below the $0.60 area). Sell Range - $1.50 to $1.75. Previous close - $0.81.
IMNR - Buy Range - $1.25 to $1.50 (risk to a break below the $1.10 area). Sell Range - $2.25 to $2.50. Previous close - $1.40.
والاخير بيوتكنولوجي
دورة المؤشرنت للتحليل الفني
50 دينار كويتي